Naz Reid (Minnesota Timberwolves) with a block vs the Brooklyn Nets, 04/13/2021
Naz Reid (Minnesota Timberwolves) with a block vs the Brooklyn Nets, 04/13/2021
Dehradun (Uttarakhand) [India], May 18 (ANI): The Uttarakhand government on Tuesday announced that it will control the distribution of Amphotericin B, an antifungal drug used for the treatment of black fungus.
Co-stars Nicole Kidman and Ewan McGregor revisit their 2001 musical hit directed by Baz Luhrmann. "I never doubted that the film would work."
Microsoft's Xbox Game Pass Ultimate subscription service offers tons of top-rated titles, and you get three months for 98% off right now—find out how.
CHARLESTON, W.Va. (AP) — A drug company executive testifying in a landmark trial against three large opioid distributors has continued to blame the Drug Enforcement Administration for West Virginia's addiction epidemic, saying his company's internal controls went beyond what regulations require. David May, the vice president of corporate security and diversion control for the AmerisourceBergen Drug Co., testified Monday that the company's abuse prevention systems have gone beyond the DEA's expectations and federal regulations, and have been improved over the years through more digital monitoring and training, according to The Herald-Dispatch. The testimony came in a civil case brought by Cabell County and the city of Huntington that accuses AmerisourceBergen, Cardinal Health Inc. and McKesson Corp. of fueling the U.S. opioid epidemic. An expert witness for the county and Huntington city used data compiled by the federal government to show that pharmaceutical distributors shipped nearly 128 million doses of prescription opioids to the county from 2006 to 2014 — or more than 140 a year for every man, woman and child in the county. The companies, in turn, say poor communication and pill quotas set by federal agents are to blame, along with a rise in prescriptions written by doctors. The regulations identify a suspicious order as one of unusual quantity, one that deviates from the usual pattern or one that is frequent, May testified. There's no set quantity that determines whether an order would be flagged, and no additional guidance on determining suspicious activity, he said. Last week, Cabell County attorney Paul T. Farrell Jr. pointed to an internal memo noting how many pills pharmacies could order without triggering an alert. The memo said a small pharmacy could order 350,000 hydrocodone or oxycodone pills a year, a medium pharmacy could order 760,000 and a large pharmacy over 1 million, the newspaper said. AmerisourceBergen alone shipped 1.9 million and 1.5 million doses of oxycodone to McCloud Family and Drug Emporium pharmacies from 2006-2014, Cabell County attorney Mark Pifko said. Farrell also showed Mays a 2007 letter from the DEA with instructions for wholesalers including determining whether orders are suspicious. Similar lawsuits have resulted in multimillion-dollar settlements; this is the first to be tried in a federal court. The result could have huge effects on hundreds of similar lawsuits filed across the country. Huntington was once ground zero for the addiction epidemic until a quick response program that formed in 2017 drove the overdose rate down. But the pandemic undid much of the progress. The Associated Press
Denver Broncos wide receiver Courtland Sutton feels he'll be ready to participate at the start of training camp. Sutton, 25, is working his way back from a torn ACL sustained in the Broncos' 26-21 loss to the Pittsburgh Steelers in Week 2 of last season. Sutton recorded 72 receptions for 1,112 yards and six touchdowns during his Pro Bowl season in 2019.
A leading U.S. banking regulator announced Tuesday it was reconsidering a recently updated rule on fair lending standards, setting aside an effort finalized under the Trump administration. The Office of the Comptroller of the Currency said it was revisiting a rule update completed in 2020 around the Community Reinvestment Act, a 1977 community lending law that requires banks to show how they are supporting lower-income communities. The move effectively acknowledges that the OCC is abandoning earlier efforts to update the rules single-handedly.
Spieth won the Masters and US Open in 2015 before adding the Open at Royal Birkdale two years later.
Fort Worth is eyeing more tech jobs, this time with a relocation from California.
We aren't the two-faced, gossipy flakes of the zodiac that the Internet would have you believe..
National Geographic sets Thanksgiving weekend as the airdate for its limited series, THE HOT ZONE: ANTHRAX, starring Daniel Dae Kim and Tony Goldwyn. The three-night event will premiere Sunday, November 28. The first season of THE HOT ZONE focused on the Ebola outbreak and became the network’s most-watched scripted series ever.
New Delhi [India], May 18 (ANI): Delhi Police has arrested three persons for allegedly preparing fake COVID-19 RT-PCR test reports.
New Delhi [India], May 18 (ANI): Cyclone Tauktae will move North-Northeastwards and weaken gradually into a deep depression in the next three hours, informed India Meteorological Department (IMD) on Tuesday.
The NBA's Coach of the Year recipient as voted on by media has not been announced.
DETROIT (AP) — Kia is recalling more than 440,000 cars and SUVs in the U.S. for a second time to fix a problem that can cause engine fires. And the automaker is telling owners to park them outdoors and away from structures because fires could happen when the engines aren't running. The recall covers certain Optima sedans from 2013 through 2015 and Sorento SUVs from 2014 and 2015. The same vehicles were recalled last year because brake fluid can leak into a control computer, causing an electrical short. That can increase the risk of fire even when the vehicles are parked. This time dealers will install a new fuse, inspect the computers, and replace them if needed. Owners will get recall notification letters starting July 2. Documents posted Tuesday by U.S. safety regulators say the new fuse has a lower amperage rating, mitigating the potential for fire. Kia says in the documents that it has customer complaints of six fires in Optimas and two in Sorentos involving “isolated melting.” One dealer reported melting in an Optima that had the previous recall fix. There were no reports of injuries or crashes, it said. The Associated Press
The incoming DUP leader said he had ‘no intention whatsoever’ of endangering devolution.
First Steps estimates more than 1,300 families will benefit from the new scholarship program during the upcoming school year.
Youri Tielemans’ long-range winner settled the Wembley clash for the Foxes’ first ever FA Cup, but now it’s all about the race for Champions League qualification. Defeats to Arsenal and a draw to Brighton have allowed Liverpool to close the gap to just one point with two remaining - goalkeeper Alisson Becker’s remarkable last-minute winner against West Brom could be key. As Thomas Tuchel said this week, his main focus when replacing Frank Lampard was to finish in the top four, and his team must win tonight.
CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer, and Dr. Bankole Johnson, Chief Medical Officer, have been featured on multiple news broadcasts nationwide regarding the ‘Second Pandemic of Addiction’ arising from the COVID-19 pandemic. Recent interviews: On May 17, 2021, Mr. Stilley appeared on KCTV, NBC, a Meredith Corporation company, where he discussed topics related to the Second Pandemic of Addiction. The dramatic increase in alcohol abuse that has occurred during the COVID-19 pandemic has created the Second Pandemic of Addiction, which is expected to result in greater fatalities and last years longer than the COVID-19 pandemic itself.There is a significant unmet need for new treatments, medicines and resources to meet this new crisis.One such option for combatting this emerging crisis is Adial’s Phase 3 drug candidate, AD04, which is a genetically targeted medicine to treat Alcohol Use disorder. On May 17, 2021, Dr. Bankole Johnson appeared on CBSN, cbsnews.com, and Yahoo! News, where he discussed how alcohol’s effects are disproportionately affecting women during the Second Pandemic. The NASW Foundation reported that women are seeing a 41% increase in abusive drinking over the last year.A nationwide survey from the American Psychological Association shows nearly 1 in 4 women have increased abusive drinking during the pandemic. That rate nearly doubled for women with children between 5 and 7.The NASW also reported that up to 150,000 more people could die due to increased drinking during the pandemic. On May 14, 2021, Mr. Stilley appeared on WJLA ABC 7, Washington DC, where he discussed how alcohol abuse was a growing problem before COVID-19 but accelerated during the lockdowns so that it is now worse and becoming the Second Pandemic. Online sales of alcohol skyrocketed 234% in April 2020 compared to the year before according to Nielsen IQ research.Adial’s landmark ONWARD™ Phase 3 pivotal clinical trial includes 290 participants in 7 countries.In Adial’s Phase 2 clinical trial of AD04, patients drank almost 50% less often and almost 60% less when they drank. Links to the above segments are also available on the media section of Adial Pharmaceuticals’ web site. Dr. Johnson is also a regular contributor to BNC.com. For more information, please go to www.adialpharma.com or follow the Company on Twitter @AdialPharm, or the CEO @BillStilley. About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity, and the Company develops adenosine analogs for the treatment of pain and other disorders. Additional information is available at www.adialpharma.com. About the Landmark ONWARD™ Pivotal Phase 3 Clinical Trial The ONWARD trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with Alcohol Use Disorder (AUD) and selected polymorphisms in the serotonin transporter and receptor genes. Patients are genetically screened prior to enrollment in the ONWARD trial so that only genetically positive patients are enrolled. The primary endpoint for analysis of efficacy is the change from baseline in the monthly number of heavy drinking days during the last 8 weeks of the 24-week treatment period. ONWARD is currently being conducted in 25 clinical sites in seven countries in Scandinavia and Central and Eastern Europe (Sweden, Finland, Poland, Latvia, Estonia, Bulgaria and Croatia). The principal investigator is Professor Hannu E.R. Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki. Forward-looking Statements This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the Second Pandemic of Addiction that occurred during the COVID-19 pandemic resulting in greater fatalities and lasting years longer than the COVID-19 pandemic itself and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, the duration and scope of the Second Pandemic of Addiction, our ability to enroll patients within the timelines anticipated and complete clinical trials on time and achieve desired results and benefits as expected, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. Contact:Crescendo Communications, LLCDavid Waldman / Natalya RudmanTel: 212-671-1021Email: email@example.com
Luise Kaish & Morton Kaish Luise Kaish sculpting Morton Kaish bust at Syracuse University, 1949 SYRACUSE, N.Y., May 18, 2021 (GLOBE NEWSWIRE) -- The Syracuse University Art Museum today announced a major gift from artists and Syracuse University alumni Luise ’46, G’51 and Morton ’49 Kaish. The gift establishes the Luise and Morton Kaish Gallery Endowed Fund and creates the Kaish Fellows program. The new Fellows program will provide funding to enable undergraduate students from every discipline to undertake original research on the permanent art collection and to work with Museum staff on exhibitions, scholarly publications, and public programming. The philanthropic gift to support undergraduate research at Syracuse University is unique as few programs such as this are available for undergraduate level students at peer academic museums. The Fellows programs also continues the dedication of the University resources and staff to support research and creative work by current and future students. The first Kaish Fellow will be appointed by the Museum in Fall 2021. The gift also includes the naming of a Museum gallery as well as a selection of artworks by Luise and Morton Kaish, which will enter the permanent collection. Both artists are currently represented in the collection. “We are so grateful to Morton and Melissa for their deeply meaningful and impactful gift,” said Vanja Malloy, Museum director and chief curator. “The endowment will enable students to experience firsthand the power of art to act as a catalyst that transcends – and sometimes subverts – boundaries. Luise explored that power throughout her career as an artist and educator. As an institution fostering exchange and knowledge-building, the gift will provide opportunities for students to experiment, innovate, and produce new scholarship. Supporting the University’s Forever Orange Campaign, the gift will also broaden the Museum's academic program. The Kaishs' generosity and legacy will fuel a new, expanded vision for the Museum, our campus communities, and beyond.” Luise (19252013) and Morton Kaish (b. 1927) are nationally recognized artists whose artwork is held by some of the world’s most prestigious museums, including the Metropolitan Museum of Art, Smithsonian American Art Museum, Jewish Museum, and the British Museum. “Luise was lauded in her day by Harold Rosenberg, John Canaday, and other influential critics, and she exhibited at the Museum of Modern Art, Sculpture Center, Whitney Museum of American Art, and other leading institutions, including a retrospective at the Jewish Museum in 1973,” said Maura Reilly, curator of Luise’s forthcoming retrospective. “Morton has been equally prolific and successful, with a celebrated career as a widely exhibited and respected painter,” Reilly continued, noting also that the Louise and Bernard Palitz Gallery at Syracuse University’s Lubin House, located in New York City, will present an important exhibition of his prints spanning seven decades in Fall 2021. The University’s longstanding commitment to interdisciplinary research and campus-wide curriculum integration resonated with their time as students. Their wide-ranging academic experiences benefited from a variety of viewpoints and pursuits. This pedagogical grounding influenced the Kaishs' artistic practices and creative output both as students in the School of Art and throughout their lives. Their daughter, Melissa Kaish Dorfman, recalls being surrounded by scholars, composers, writers, and architects who were part of her parent’s social and intellectual circles while she was growing up. “The arts must not be siloed,” she said. “Multidisciplinary experiences enrich the artist’s world view. My parents helped me listen to the world with my eyes. They encouraged me to learn not just by looking, but to see new levels of understanding—how art draws upon science, philosophy, politics, religion, music, nature. Replicating that type of fertile, dynamic environment for liberal art students is a goal that my father and I envision will be supported through this gift." About the Syracuse University Art Museum The Syracuse University Art Museum is the campus art museum of Syracuse University. It strives to be a place of rigorous interdisciplinary research, creative thinking, and mindfulness, as well as an inclusive space that serves as a forum for a broad range of discussions that bring people together, uniting the wider community with students, faculty, and staff. A partner of Syracuse University’s Coalition of Museum and Art Centers, the Museum presents up to 20 exhibitions annually, scores of public programs, and an active schedule of class visits. It also manages the Palitz Gallery at the Syracuse University Lubin House in New York City where up to six exhibitions a year are presented. The Museum’s permanent collection of 45,000 artworks from 3500 BCE to present day includes important holdings from many areas of the world. Over the past 35 years, the Museum has shared much of its art collection with peer institutions across the country through its traveling exhibition program. MEDIA CONTACTS: Syracuse University Art Museum - Emily Dittman, Associate Director, SU Art Museum, firstname.lastname@example.org | museum.syr.edu Kaish Family Art Project - Libby Mark or Heather Meltzer, Bow Bridge Communications, email@example.com | 347-460-5566 | kaishfamilyartproject.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/35c71aab-9914-44c2-af48-7946fc20ad4e
United will tonight be one of the first Premier League clubs to welcome back fans for the first time since December as relegated Fulham come to Old Trafford. Amid the ongoing sea of discontent among supporters over the ongoing ownership of the Glazer family, against whom fans have twice protested in recent weeks, United will look to finish the season strongly ahead of next week’s Europa League Final. As many as 10,000 United fans are expected tonight and will be anticipating a reaction following defeats to both Leicester City and Liverpool last week.